Results from a phase II, open-label, randomized study (SIGN) comparing gefitinib with docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer

T. Cufer; E. Vrdoljak

doi:10.1200/jco.2005.23.16_suppl.7035

Results from a phase II, open-label, randomized study (SIGN) comparing gefitinib with docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer

Journal of Clinical Oncology ◽

10.1200/jco.2005.23.16_suppl.7035 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 7035-7035 ◽

Cited By ~ 7

Author(s):

T. Cufer ◽

E. Vrdoljak

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Randomized Study ◽

Small Cell ◽

Advanced Stage ◽

Second Line ◽

Small Cell Lung ◽

Open Label ◽

Second Line Therapy ◽

Line Therapy

Download Full-text

PD-070 SIGN: A Phase II, open-label, randomized study comparinggefitinib (IRESSA) with docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer

Lung Cancer ◽

10.1016/s0169-5002(05)80403-9 ◽

2005 ◽

Vol 49 ◽

pp. S87 ◽

Cited By ~ 1

Author(s):

T. Cufer ◽

E. Vrdoljak

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Randomized Study ◽

Small Cell ◽

Advanced Stage ◽

Second Line ◽

Small Cell Lung ◽

Open Label ◽

Second Line Therapy ◽

Line Therapy

Download Full-text

Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer

Anti-Cancer Drugs ◽

10.1097/01.cad.0000203381.99490.ab ◽

2006 ◽

Vol 17 (4) ◽

pp. 401-409 ◽

Cited By ~ 100

Author(s):

Tanja Cufer ◽

Eduard Vrdoljak ◽

Rabab Gaafar ◽

Inci Erensoy ◽

Kristine Pemberton

Keyword(s):

Lung Cancer ◽

Randomized Study ◽

Single Agent ◽

Small Cell ◽

Advanced Stage ◽

Second Line ◽

Small Cell Lung ◽

Open Label ◽

Second Line Therapy ◽

Line Therapy

Download Full-text

Open-label phase II study of S-1 as second-line therapy for patients with advanced non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.7580 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 7580-7580 ◽

Cited By ~ 1

Author(s):

R. Govindan ◽

C. Zergebel ◽

K. Saito ◽

J. H. Schiller

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii Study ◽

Small Cell ◽

Second Line ◽

Small Cell Lung ◽

Open Label ◽

Second Line Therapy ◽

Line Therapy ◽

Open Label Phase

Download Full-text

Second-line therapy with gefitinib in combination with docetaxel for advanced non-small cell lung cancer: a phase II randomized study

Targeted Oncology ◽

10.1007/s11523-007-0042-9 ◽

2007 ◽

Vol 2 (2) ◽

pp. 63-71

Author(s):

G. Robinet ◽

F. Barlesi ◽

P. Fournel ◽

H. Berard ◽

R. Corre ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Cell Lung Cancer ◽

Randomized Study ◽

Small Cell ◽

Second Line ◽

Small Cell Lung ◽

Second Line Therapy ◽

Line Therapy

Download Full-text

Phase II, Double-Blinded, Randomized Study of Enzastaurin Plus Pemetrexed as Second-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer

Journal of Thoracic Oncology ◽

10.1097/jto.0b013e3181cee24f ◽

2010 ◽

Vol 5 (3) ◽

pp. 369-375 ◽

Cited By ~ 26

Author(s):

Alberto Chiappori ◽

Gerold Bepler ◽

Fabrice Barlesi ◽

Jean-Charles Soria ◽

Martin Reck ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Randomized Study ◽

Small Cell ◽

Second Line ◽

Small Cell Lung ◽

Second Line Therapy ◽

Line Therapy ◽

Double Blinded

Download Full-text

An Open-Label, Multicenter, Randomized Phase Ib/II Study of Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second-Line Therapy in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer

Clinical Lung Cancer ◽

10.1016/j.cllc.2014.10.001 ◽

2015 ◽

Vol 16 (2) ◽

pp. 92-99 ◽

Cited By ~ 10

Author(s):

Cornelius F. Waller ◽

Ihor Vynnychenko ◽

Igor Bondarenko ◽

Yaroslav Shparyk ◽

Jeffrey P. Hodge ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Second Line ◽

Small Cell Lung ◽

Open Label ◽

Second Line Therapy ◽

Eribulin Mesylate ◽

Phase Ib ◽

Line Therapy

Download Full-text

Comparison of Single Agent Gemcitabine and Docetaxel in Second-Line Therapy for Advanced Stage Non-Small Cell Lung Cancer in a University Hospital in Turkey

Asian Pacific Journal of Cancer Prevention ◽

10.7314/apjcp.2015.16.17.7859 ◽

2015 ◽

Vol 16 (17) ◽

pp. 7859-7863 ◽

Cited By ~ 2

Author(s):

Fatma Yildirim ◽

Ayse Baha ◽

Ahmet Selim Yurdakul ◽

Can Ozturk

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Single Agent ◽

Small Cell ◽

University Hospital ◽

Advanced Stage ◽

Second Line ◽

Small Cell Lung ◽

Second Line Therapy ◽

Line Therapy

Download Full-text

Efficacy and Safety of Rovalpituzumab Tesirine Compared with Topotecan as Second-Line Therapy in DLL3-High Small Cell Lung Cancer: Results from the Phase 3 TAHOE Study

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2021.02.009 ◽

2021 ◽

Author(s):

Fiona Blackhall ◽

Kevin Jao ◽

Laurent Greillier ◽

Byoung Chul Cho ◽

Konstantin Penkov ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Second Line ◽

Efficacy And Safety ◽

Small Cell Lung ◽

Second Line Therapy ◽

Phase 3 ◽

Line Therapy

Download Full-text

Second-line therapy for non-small cell lung cancer in clinical practice: final results and treatment pathways from the SELECTTION observational study

Current Medical Research and Opinion ◽

10.1185/03007995.2012.703133 ◽

2012 ◽

Vol 28 (8) ◽

pp. 1253-1262 ◽

Cited By ~ 7

Author(s):

Alain Vergnenegre ◽

Egbert F. Smit ◽

Elisabeth Toy ◽

Barbara Parente ◽

Stephan Schmitz ◽

...

Keyword(s):

Lung Cancer ◽

Clinical Practice ◽

Observational Study ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Second Line ◽

Small Cell Lung ◽

Second Line Therapy ◽

Treatment Pathways ◽

Line Therapy

Download Full-text

Results of the safety run-in part of the METAL (METformin in Advanced Lung cancer) study: a multicentre, open-label phase I–II study of metformin with erlotinib in second-line therapy of patients with stage IV non-small-cell lung cancer

ESMO Open ◽

10.1136/esmoopen-2016-000132 ◽

2017 ◽

Vol 2 (2) ◽

pp. e000132 ◽

Cited By ~ 20

Author(s):

Floriana Morgillo ◽

Morena Fasano ◽

Carminia Maria Della Corte ◽

Ferdinando Carlo Sasso ◽

Federica Papaccio ◽

...

Keyword(s):

Lung Cancer ◽

Stage Iv ◽

Small Cell ◽

Advanced Lung Cancer ◽

Second Line ◽

Small Cell Lung ◽

Open Label ◽

Second Line Therapy ◽

Line Therapy ◽

Open Label Phase

Download Full-text